Study Title
Effect of a Mediterranean Diet Supplemented With Nuts on Metabolic Syndrome Status; One-Year Results of the PREDIMED Randomized Trial
Archives of Internal Medicine- Journal of the American Medical Association

Jordi Salas-Salvado´ , MD, PhD; Joan Ferna´ ndez-Ballart, MD, PhD; Emilio Ros, MD, PhD;
Miguel-Angel Martı´nez-Gonza´ lez, MD, PhD; Montserrat Fito´ , MD, PhD; Ramon Estruch, MD, PhD;
Dolores Corella, DPharm, PhD; Miquel Fiol, MD, PhD; Enrique Go´mez-Gracia, MD, PhD; Fernando Aro´s, MD, PhD;
Gemma Flores, MD; Jose´ Lapetra, MD, PhD; Rosa Lamuela-Ravento´s, DPharm, PhD;
Valentina Ruiz-Gutie´rrez, DPharm, PhD; Mònica Bullo´ , PhD; Josep Basora, MD; Marı´a-Isabel Covas, DPharm, PhD;
for the PREDIMED Study Investigators


Background: Epidemiological studies suggest that the Mediterranean diet (MedDiet) may reduce the risk of developing the metabolic syndrome (MetS). We compared the 1-year effect of 2 behavioral interventions to implement the MedDiet vs advice on a low-fat diet on MetS status.
Methods: A total of 1224 participants were recruited from the PREDIMED (Prevencio´n con Dieta Mediterra´nea) Study, a multicenter, 3-arm, randomized clinical trial to determine the efficacy of the MedDiet on the primary prevention of cardiovascular disease. Participants were older subjects at high risk for cardiovascular disease. Interventions were quarterly education about the MedDiet plus provision of either 1 L/wk of virgin olive oil (MedDiet + VOO) or 30 g/d of mixed nuts (MedDiet + nuts), and advice on a low-fat diet (control diet). All diets were ad libitum, and there was no increase in physical activity for any of the interventions. Lifestyle variables and MetS features as defined by the National Cholesterol Education Program Adult Treatment Panel III criteria were assessed.
Results: At baseline, 61.4% of participants met criteria for the MetS. One-year prevalence was reduced by 6.7%, 13.7%, and 2.0% in the MedDiet + VOO, MedDiet + nuts, and control diet groups, respectively (MedDiet + nuts vs control groups, P=.01; MedDiet + VOO vs control group, P =.18). Incident rates of the MetS were not significantly different among groups (22.9%, 17.9%, and 23.4%, respectively). After adjustment for sex, age, baseline obesity status, and weight changes, the odds ratios for reversion of MetS were 1.3 (95% confidence interval, 0.8-2.1) for the MedDiet + VOO group and 1.7 (1.1- 2.6) for the MedDiet + nuts group compared with the control diet group.
Conclusion: A traditional MedDiet enriched with nuts could be a useful tool in the management of the MetS.

December 1, 2008
View study

Share This

Related Topics

Metabolic SyndromeMediterranean DietNuts

Dr. Perlmutter is one of the leading lights in medicine today, illuminating the path for solving chronic illness

Mark Hyman, MD